GRWD5769

GRWD5769 is a first-in-class anti-cancer drug which acts as a selective inhibitor of the enzyme endoplasmic reticulum aminopeptidase 1 (ERAP1).

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

GRWD5769 is a first-in-class anti-cancer drug which acts as a selective inhibitor of the enzyme endoplasmic reticulum aminopeptidase 1 (ERAP1). It is in human clinical trials for the treatment of solid tumours including squamous cell carcinoma and cervical and liver cancers.

Grey Wolf Therapeutics has filed several patents claiming phenylsulfamoyl benzoic acid derivatives as selective ERAP1 inhibitors useful in the treatment of cancer, but the exact chemical structure of GRWD5769 does not appear to have been disclosed as yet.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1359405251 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.